Skip to main content

Quality of life higher with dimethyl fumarate than Fingolimod (17/10/16)

According to a recent update on the Univadis website, patient-reported quality-of-life variables showed a preference for dimethyl fumarate compared to Fingolimod. Head-to-head trials comparing of fingolimod and DMF have not been conducted in the past.

Although time-released dimethyl fumarate (DMF; Tecfidera) and Fingolimod (Gilenya) showed similar reductions in relapse rates and disability progression among individuals with relapsing-remitting multiple sclerosis (RRMS) in an indirect comparison study, patient-reported quality-of-life variables showed a preference for DMF.

Source: Univadis, © 2016 Aptus Health, Inc (17/10/16)